Baird raised the firm’s price target on Iqvia to $248 from $239 and keeps an Outperform rating on the shares. The firm said the quarter is probably fine, but the buyside is increasingly expecting cuts. Baird believes the eventual 2024 guide could be below consensus, but not materially so and its more about ending the slow bleed of talk-downs and minor cuts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IQV:
- Iqvia price target lowered to $240 from $260 at Evercore ISI
- Agilon Health price target lowered to $20 from $21 at Evercore ISI
- Iqvia price target lowered to $229 from $250 at Mizuho
- Iqvia enters pact with Argenx to provide safety systems, services
- Iqvia price target lowered to $245 from $250 at Barclays